Current landscape for T-cell targeting in autoimmunity and transplantation

Immunotherapy

Volumn 3, Issue 7, 2011, Pages 853-870

  Getts, Daniel R ^a,b   Shankar, Sushma ^c   Chastain, Emily M L ^a   Martin, Aaron ^a   Getts, Meghann Teague ^a,d   Wood, Kathryn ^c   Miller, Stephen D ^a  

^a NORTHWESTERN UNIVERSITY   (United States)

^b Tolera Therapeutics Inc   (United States)

^c UNIVERSITY OF OXFORD   (United Kingdom)

^d Getts Consulting and Project Management   (United States)

Author keywords

autoimmunity; chimerism; immune suppression; infection; maintenance suppression; T cell tolerance; transplantation

Indexed keywords

ABATACEPT; ALEMTUZUMAB; AZATHIOPRINE; BASILIXIMAB; BELATACEPT; CALCINEURIN INHIBITOR; CYCLOSPORIN; CYCLOSPORIN A; CYTOTOXIC T LYMPHOCYTE ANTIGEN 4 ANTIBODY; DACLIZUMAB; FINGOLIMOD; IMMUNOSUPPRESSIVE AGENT; METHOTREXATE; MYCOPHENOLIC ACID; MYCOPHENOLIC ACID 2 MORPHOLINOETHYL ESTER; OKT 3; PLACEBO; PREDNISOLONE; RAPAMYCIN; SOTRASTAURIN; STEROID; TACROLIMUS; TASOCITINIB; THYMOCYTE ANTIBODY;

ACNE; ANEMIA; ANTIGEN PRESENTING CELL; ANTIGEN RECOGNITION; AUTOIMMUNE DISEASE; AUTOIMMUNITY; BLOOD VESSEL OCCLUSION; BLURRED VISION; BONE MARROW DEPRESSION; BRAIN DISEASE; BRAIN ISCHEMIA; CARDIOVASCULAR DISEASE; CELL DIFFERENTIATION; CELL PROLIFERATION; CELL THERAPY; CELL TRANSPLANTATION; CLINICAL PRACTICE; CLONAL ANERGY; CONSTIPATION; CYTOKINE RELEASE SYNDROME; DELAYED GRAFT FUNCTION; DERMATITIS; DIABETES MELLITUS; DISEASE COURSE; DISEASE PREDISPOSITION; EDEMA; FLUID RETENTION; GASTROINTESTINAL DISEASE; GINGIVA HYPERPLASIA; GRAFT REJECTION; HAIR LOSS; HEMATOPOIETIC STEM CELL TRANSPLANTATION; HEPATITIS; HIRSUTISM; HOMEOSTASIS; HUMAN; HYPERLIPIDEMIA; HYPERTENSION; IMMUNE DEFICIENCY; IMMUNE RESPONSE; IMMUNE SYSTEM; IMMUNOLOGICAL TOLERANCE; IMMUNOREGULATION; IMMUNOSUPPRESSIVE TREATMENT; INFECTION; KIDNEY DISEASE; KIDNEY GRAFT REJECTION; LIVER TOXICITY; LOW DRUG DOSE; LUNG FIBROSIS; LYMPHOCYTE DEPLETION; MEGALOCYTOSIS; MOUTH ULCER; MULTIPLE SCLEROSIS; NEPHROTOXICITY; NEUROTOXICITY; NEUTROPENIA; NONHUMAN; OPPORTUNISTIC INFECTION; ORGAN TRANSPLANTATION; OSTEOPOROSIS; PANCREATITIS; PATHOGENESIS; PEPTIC ULCER; PHASE 2 CLINICAL TRIAL (TOPIC); PNEUMONIA; PRIORITY JOURNAL; PROTENURIA; PSYCHOSIS; RANDOMIZED CONTROLLED TRIAL (TOPIC); REVIEW; RHEUMATOID ARTHRITIS; SIDE EFFECT; SINGLE DRUG DOSE; T LYMPHOCYTE; TARGET CELL; THROMBOTIC THROMBOCYTOPENIC PURPURA; TREMOR; WEIGHT GAIN; WOUND HEALING; WOUND HEALING IMPAIRMENT;

AUTOIMMUNE DISEASES; CALCINEURIN; CELL DIFFERENTIATION; CELL PROLIFERATION; CYTOKINES; HEMATOPOIETIC STEM CELL TRANSPLANTATION; HUMANS; IMMUNOSUPPRESSION; IMMUNOSUPPRESSIVE AGENTS; JANUS KINASE 3; ORGAN TRANSPLANTATION; PROTEIN KINASE C; PYRIMIDINES; PYRROLES; QUINAZOLINES; RECEPTORS, CYTOKINE; T-LYMPHOCYTES; TRANSPLANTATION IMMUNOLOGY; TRANSPLANTATION TOLERANCE;

EID: 79960516712     PISSN: 1750743X     EISSN: 17507448     Source Type: Journal    
DOI: 10.2217/imt.11.61     Document Type: Review

References (131)

1. Manilay JO, Waneck GL, Sykes M. Altered expression of Ly-49 receptors on NK cells developing in mixed allogeneic bone marrow chimeras. Int. Immunol. 10(12), 1943-1955 (1998).
2. Ciancio G, Burke GW, Gaynor JJ et al. The use of Campath-1H as induction therapy in renal transplantation: preliminary results. Transplantation 78(3), 426-433 (2004).
3. Lombardi G, Sidhu S, Batchelor R, Lechler R. Anergic T cells as suppressor cells in vitro. Science 264(5165), 1587-1589 (1994).
4. Bishop GA, Sun J, Sheil AG, Mccaughan GW. High-dose/activation-associated tolerance: a mechanism for allograft tolerance. Transplantation 64(10), 1377-1382 (1997).
5. Preville X, Flacher M, Lemauff B et al. Mechanisms involved in antithymocyte globulin immunosuppressive activity in a nonhuman primate model. Transplantation 71(3), 460-468 (2001).
6. Naujokat C, Berges C, Fuchs D, Sadeghi M, Opelz G, Daniel V. Antithymocyte globulins suppress dendritic cell function by multiple mechanisms. Transplantation 83(4), 485-497 (2007).
7. Dalle JH, Dardari R, Menezes J, Cordeiro P, Champagne MA, Duval M. Binding of thymoglobulin to natural killer cells leads to cell activation and interferon-g production. Transplantation 87(4), 473-481 (2009).
8. Stauch D, Dernier A, Sarmiento Marchese E et al. Targeting of natural killer cells by rabbit antithymocyte globulin and campath-1H: similar effects independent of specificity. PLoS One 4(3), e4709 (2009).
9. Noel C, Abramowicz D, Durand D et al. Daclizumab versus antithymocyte globulin in high-immunological-risk renal transplant recipients. J. Am. Soc. Nephrol. 20(6), 1385-1392 (2009).
10. Lebranchu Y, Bridoux F, Buchler M et al. Immunoprophylaxis with basiliximab compared with antithymocyte globulin in renal transplant patients receiving MMF-containing triple therapy. Am. J. Transplant. 2(1), 48-56 (2002).
11. Gaber AO, First MR, Tesi RJ et l. Results of the double-blind, randomized, multicenter, Phase III clinical trial of thymoglobulin versus ATGAM in the treatment of acute graft rejection episodes after renal transplantation. Transplantation 66(1), 29-37 (1998).
12. Brennan DC, Flavin K, Lowell JA et al. Leukocyte response to thymoglobulin or ATGAM for induction immunosuppression in a randomized, double-blind clinical trial in renal transplant recipients. Transplantation Proceedings 31(Suppl. 3B), S16-S18 (1999).
13. Shapiro R, Basu A, Tan H et al. Kidney transplantation under minimal immunosuppression after pretransplant lymphoid depletion with thymoglobulin or Campath. J. Am. Coll. Surg. 200(4), 505-515; quiz A559-561 (2005).
14. + regulatory T cells. J. Am. Soc. Nephrol. 17(10), 2844-2853 (2006).
15. Lacorcia G, Swistak M, Lawendowski C et al. Polyclonal rabbit antithymocyte globulin exhibits consistent immunosuppressive capabilities beyond cell depletion. Transplantation 87(7), 966-974 (2009).
16. Mourad G, Garrigue V, Squifflet JP et al. Induction versus noninduction in renal transplant recipients with tacrolimus-based immunosuppression. Transplantation 72(6), 1050-1055 (2001).
17. Charpentier B, Rostaing L, Berthoux F et al. A three-arm study comparing immediate tacrolimus therapy with antithymocyte globulin induction therapy followed by tacrolimus or cyclosporine A in adult renal transplant recipients. Transplantation 75(6), 844-851 (2003).
18. Mourad G, Rostaing L, Legendre C, Garrigue V, Thervet E, Durand D. Sequential protocols using basiliximab versus antithymocyte globulins in renal-transplant patients receiving mycophenolate mofetil and steroids. Transplantation 78(4), 584-590 (2004).
19. Abou-Ayache R, Buchler M, Lepogamp P et al. CMV infections after two doses of daclizumab versus thymoglobulin in renal transplant patients receiving mycophenolate mofetil, steroids and delayed cyclosporine A. Nephrol. Dial. Transplant. 23(6), 2024-2032 (2008).
20. Rajab A, Pelletier RP, Henry ML, Ferguson RM. Excellent clinical outcomes in primary kidney transplant recipients treated with steroid-free maintenance immunosuppression. Clin. Transplan. 20(5), 537-546 (2006).
21. Matas AJ, Kandaswamy R, Gillingham KJ et al. Prednisone-free maintenance immunosuppression-a 5-year experience. Am. J. Transplant. 5(10), 2473-2478 (2005).
22. Birkeland SA. Steroid-free immunosuppression in renal transplantation: a long-term follow-up of 100 consecutive patients. Transplantation 71(8), 1089-1090 (2001).
23. Hardinger KL, Rhee S, Buchanan P et al. A prospective, randomized, double-blinded comparison of thymoglobulin versus Atgam for induction immunosuppressive therapy: 10-year results. Transplantation 86(7), 947-952 (2008).
24. Brennan DC, Daller JA, Lake KD, Cibrik D, Del Castillo D. Rabbit antithymocyte globulin versus basiliximab in renal transplantation. N. Engl. J. Med. 355(19), 1967-1977 (2006).
25. Morris PJ, Russell NK. Alemtuzumab (Campath-1H): a systematic review in organ transplantation. Transplantation 81(10), 1361-1367 (2006).
26. + T cells in alemtuzumab-depleted kidney transplant recipients treated with reduced immunosuppression. Am. J. Transplant. 8(2), 338-347 (2008).
27. Kirk AD, Hale DA, Mannon RB et al. Results from a human renal allograft tolerance trial evaluating the humanized CD52-specific monoclonal antibody alemtuzumab (CAMPATH-1H).Transplantation 76(1), 120-129 (2003).
28. Trzonkowski P, Zilvetti M, Friend P, Wood KJ. Recipient memory-like lymphocytes remain unresponsive to graft antigens after CAMPATH-1H induction with reduced maintenance immunosuppression. Transplantation 82(10), 1342-1351 (2006).
29. Knechtle SJ, Pirsch JD, H Fechner J Jr et al. Campath-1H induction plus rapamycin monotherapy for renal transplantation: results of a pilot study. Am. J. Transplant. 3(6), 722-730 (2003).
30. Bloom DD, Hu H, Fechner JH, Knechtle SJ. T-lymphocyte alloresponses of Campath-1H-treated kidney transplant patients. Transplantation 81(1), 81-87 (2006).
31. Calne R, Friend P, Moffatt S et al. Prope tolerance, perioperative campath 1H, and low-dose cyclosporin monotherapy in renal allograft recipients. Lancet 351(9117), 1701-1702 (1998).
32. Watson CJ, Bradley JA, Friend PJ et al. Alemtuzumab (CAMPATH 1H) induction therapy in cadaveric kidney transplantation - efficacy and safety at five years. Am. J. Transplant. 5(6), 1347-1353 (2005).
33. Wu Z, Bensinger SJ, Zhang J et al. Homeostatic proliferation is a barrier to transplantation tolerance. Nat. Med. 10(1), 87-92 (2004).
34. Vathsala A, Ona ET, Tan SY et al. Randomized trial of Alemtuzumab for prevention of graft rejection and preservation of renal function after kidney transplantation. Transplantation 80(6), 765-774 (2005).
35. Ciancio G, Burke GW, Gaynor JJ et al. A randomized trial of three renal transplant induction antibodies: early comparison of tacrolimus, mycophenolate mofetil, and steroid dosing, and newer immune-monitoring. Transplantation 80(4), 457-465 (2005).
36. Kaufman DB, Leventhal JR, Axelrod D, Gallon LG, Parker MA, Stuart FP. Alemtuzumab induction and prednisone-free maintenanc immunotherapy in kidney transplantation: comparison with basiliximab induction-long-term results. Am. J. Transplant. 5(10), 2539-2548 (2005).
37. Coles AJ, Compston DA, Selmaj KW et al. Alemtuzumab vs. interferon β-1a in early multiple sclerosis. N. Engl. J. Med. 359(17), 1786-1801 (2008).
38. Flechner SM, Friend PJ, Brockmann J et al. Alemtuzumab induction and sirolimus plus mycophenolate mofetil maintenance for CNI and steroid-free kidney transplant immunosuppression. Am. J. Transplant. 5(12), 3009-3014 (2005).
39. Kirk AD, Mannon RB, Kleiner DE et al. Results from a human renal allograft tolerance trial evaluating T-cell depletion with alemtuzumab combined with deoxyspergualin. Transplantation 80(8), 1051-1059 (2005).
40. Magliocca JF, Knechtle SJ. The evolving role of alemtuzumab (Campath-1H) for immunosuppressive therapy in organ transplantation. Transpl. Int. 19(9), 705-714 (2006).
41. Ravandi F, O'Brien S. Alemtuzumab. Expert Rev. Anticancer Ther. 5(1), 39-51 (2005).
42. Enblad G, Hagberg H, Erlanson M et al. A pilot study of alemtuzumab (anti-CD52 monoclonal antibody) therapy for patients with relapsed or chemotherapy-refractory peripheral T-cell lymphomas. Blood 103(8), 2920-2924 (2004).
43. Dearden C. The role of alemtuzumab in the management of T-cell malignancies. Semin. Oncol. 33(2 Suppl. 5), S44-S52 (2006).
44. Silveira FP, Husain S, Kwak EJ et al. Cryptococcosis in liver and kidney transplant recipients receiving anti-thymocyte globulin or alemtuzumab. Transpl. Infect. Dis. 9(1), 22-27 (2007).
45. Nath DS, Kandaswamy R, Gruessner R, Sutherland DE, Dunn DL, Humar A. Fungal infections in transplant recipients receiving alemtuzumab. Transplant. Proc. 37(2), 934-936 (2005).
46. Martin SI, Marty FM, Fiumara K, Treon SP, Gribben JG, Baden LR. Infectious complications associated with alemtuzumab use for lymphoproliferative disorders. Clin. Infect. Dis. 43(1), 16-24 (2006).
47. Abad S, Gyan E, Moachon L et al. Tuberculosis due to Mycobacterium bovis after alemtuzumab administration. Clin. Infect. Dis. 37(2), E27-E28 (2003).
48. Safdar N, Smith J, Knasinski V et al. Infections after the use of alemtuzumab in solid organ transplant recipients: a comparative study. Diagn. Microbiol. Infect. Dis. 66(1), 7-15 (2010).
49. Marcos A, Eghtesad B, Fung JJ et al. Use of alemtuzumab and tacrolimus monotherapy for cadaveric liver transplantation: with particular reference to hepatitis C virus. Transplantation 78(7), 966-971 (2004).
50. Opelz G. Efficacy of rejection prophylaxis with OKT3 in renal transplantation. Collaborative Transplant Study. Transplantation 60(11), 1220-1224 (1995).
51. Midtvedt K, Fauchald P, Lien B et al. Individualized T cell monitored administration of ATG versus OKT3 in steroid-resistant kidney graft rejection. Clin. Transplan. 17(1), 69-74 (2003).
52. Getts D, Martin A, Siemionow M, Miller S. Operational tolerance vs immune suppression, targeting the α β TCR with TOL101. Am. J. Transplant. 10(Suppl. 4), 210 (2010).
53. Getts DR, Getts MT, Mccarthy DP, Chastain EM, Miller SD. Have we overestimated the benefit of human(ized) antibodies? MAbs 2(6), 682-694 (2010).
54. Locke NR, Stankovic S, Funda Dp, Harrison LC. TCR g d intraepithelial lymphocytes are required for self-tolerance. J. Immunol. 176(11), 6553-6559 (2006).
55. Lavasani S, Dzhambazov B, Andersson M. Monoclonal antibody against T-cell receptor ab induces self-tolerance in chronic experimental autoimmune encephalomyelitis. Scand. J. Immunol. 65(1), 39-47 (2007).
56. Sempe P, Bedossa P, Richard MF, Villa MC, Bach JF, Boitard C. Anti-α/β T cell receptor monoclonal antibody provides an efficient therapy for autoimmune diabetes in nonobese diabetic (NOD) mice. Eur. J. Immunol. 21(5), 1163-1169 (1991).
57. Waid TH, Lucas BA, Amlot P et al. T10B9.1A-31 anti-T-cell monoclonal antibody: preclinical studies and clinical treatment of solid organ allograft rejection. Am. J. Kidney Dis. 14(5 Suppl. 2), 61-70 (1989).
58. Waid TH, Lucas BA, Thompson JS et al. Treatment of acute cellular kidney allograft rejection with T10B9.1A-31A anti T-cell monoclonal antibody. Transplant. Proc. 21(1 Pt 2), 1778-1784 (1989).
59. Waid TH, Lucas BA, Thompson JS et al. Treatment of acute cellular rejection with T10B9.1A-31 or OKT3 in renal allograft recipients. Transplantation 53(1), 80-86 (1992).
60. Bishop MR, Henslee-Downey PJ, Anderson JR et al. Long-term survival in advanced chronic myelogenous leukemia following bone marrow transplantation from haploidentical related donors. Bone Marrow Transplant. 18(4), 747-753 (1996).
61. Brown S, Lucas B, Waid T, Mckeown W, Tsuchida M, Thompson J. T10B9 action: the effect of anti-T-cell antibody mitogenicity and graft rejection on the first dose cytokine response. Transplant. Proc. 29(1-2), 315-316 (1997).
62. Bunin N, Aplenc R, Iannone R et al. Unrelated donor bone marrow transplantation for children with severe aplastic anemia: minimal GVHD and durable engraftment with partial T cell depletion. Bone Marrow Transplant. 35(4), 369-373 (2005).
63. Bunin N, Aplenc R, Leahey A et al. Outcomes of transplantation with partial T-cell depletion of matched or mismatched unrelated or partially matched related donor bone marrow in children and adolescents with leukemias. Bone Marrow Transplant. 35(2), 151-158 (2005).
64. Godder KT, Hazlett LJ, Abhyankar SH et al. Partially mismatched related-donor bone marrow transplantation for pediatric patients with acute leukemia: younger donors and absence of peripheral blasts improve outcome. J. Clin. Oncol. 18(9), 1856-1866 (2000).
65. Waid TH, Lucas BA, Thompson JS et al. Treatment of acute rejection with anti-T-cell antigen receptor complex alpha beta (T10B9.1A-31) or anti-CD3 (OKT3) monoclonal antibody: results of a prospective randomized double-blind trial. Transplant. Proc. 23(1 Pt 2), 1062-1065 (1991).
66. Beelen DW, Graeven U, Schulz G et al. Treatment of acute graft-versus-host disease after HLA-partially matched marrow transplantation with a monoclonal antibody (BMA031) against the T cell receptor. First results of a Phase-I/II trial. Onkologie 11(1), 56-58 (1988).
67. Beelen DW, Grosse-Wilde H, Ryschka U et al. Initial treatment of acute graft-versus-host disease with a murine monoclonal antibody directed to the human alpha/beta T cell receptor. Cancer Immunol. Immunother. 34(2), 97-102 (1991).
68. Walker C, Pichler WJ, Koponen M, Domzig W, De Weck AL: Different effects of IL-2 addition or antibody crosslinking on T-cell subset stimulation by CD3 antibodies. Cell Immunol. 101(1), 195-203 (1986).
69. Larsen CP, Pearson TC, Adams AB et al. Rational development of LEA29Y (belatacept), a high-affinity variant of CTLA4-Ig with potent immunosuppressive properties. Am. J. Transplant. 5(3), 443-453 (2005).
70. Vincenti F, Luggen M. T cell costimulation: a rational target in the therapeutic armamentarium for autoimmune diseases and transplantation. Annu. Rev. Med. 58, 347-358 (2007).
71. Ruderman EM, Pope RM. Drug insight: abatacept for the treatment of rheumatoid arthritis. Nat. Clin. Pract. Rheumatol. 2(12), 654-660 (2006).
72. Larsen Cp, Grinyo J, Medina-Pestana J et al. Belatacept-based regimens versus a cyclosporine A-based regimen in kidney transplant recipients: 2-year results from the BENEFIT and BENEFIT-EXT studies. Transplantation 90(12), 1528-1535 (2010).
73. Vincenti F, Blancho G, Durrbach A et al. Five-year safety and efficacy of belatacept in renal transplantation. J. Am. Soc. Nephrol. 21(9), 1587-1596 (2010).
74. Vincenti F, Charpentier B, Vanrenterghem Y et al. A Phase III study of belatacept-based immunosuppression regimens versus cyclosporine in renal transplant recipients (BENEFIT study).Am. J. Transplant. 10(3), 535-546 (2010).
75. Koyama S, Ishii KJ, Kumar H et al. Differential role of TLR-and RLR-signaling in the immune responses to influenza A virus infection and vaccination. J. Immunol. 179(7), 4711-4720 (2007).
76. + T cells can trigger allograft rejection. J. Immunol. 165(2), 1111-1118 (2000).
77. Webster AC, Playford EG, Higgins G, Chapman JR, Craig JC. Interleukin 2 receptor antagonists for renal transplant recipients: a meta-analysis of randomized trials. Transplantation 77(2), 166-176 (2004).
78. Vincenti F, De Andres A, Becker T et al. Interleukin-2 receptor antagonist induction in modern immunosuppression regimens for renal transplant recipients. Transpl. Int. 19(6), 446-457 (2006).
79. Amlot PL, Rawlings E, Fernando ON et al. Prolonged action of a chimeric interleukin-2 receptor (CD25) monoclonal antibody used in cadaveric renal transplantation. Transplantation 60(7), 748-756 (1995).
80. Basadonna GP, Matas AJ, Gillingham KJ et al. Early versus late acute renal allograft rejection: impact on chronic rejection. Transplantation 55(5),993-995 (1993).
81. Keown P, Balshaw R, Khorasheh S et al. Meta-analysis of basiliximab for immunoprophylaxis in renal transplantation. BioDrugs 17(4), 271-279 (2003).
82. Nashan B, Moore R, Amlot P, Schmidt AG, Abeywickrama K, Soulillou JP. Randomised trial of basiliximab versus placebo for control of acute cellular rejection in renal allograft recipients. CHIB 201 International Study Group. Lancet 350(9086), 1193-1198 (1997).
83. Calmus Y, Scheele JR, Gonzalez-Pinto I et al. Immunoprophylaxis with basiliximab, a chimeric anti-interleukin-2 receptor monoclonal antibody, in combination with azathioprine-containing triple therapy in liver transplant recipients. Liver Transpl. 8(2), 123-131 (2002).
84. Ponticelli C, Yussim A, Cambi V et al. A randomized, double-blind trial of basiliximab immunoprophylaxis plus triple therapy in kidney transplant recipients. Transplantation 72(7), 1261-1267 (2001).
85. Lawen JG, Davies EA, Mourad G et al. Randomized double-blind study of immunoprophylaxis with basiliximab, a chimeric anti-interleukin-2 receptor monoclonal antibody, in combination with mycophenolate mofetil-containing triple therapy in renal transplantation. Transplantation 75(1), 37-43 (2003).
86. Chen W, Bennett CF, Wang ME et al. Perfusion of kidneys with unformulated 'naked' intercellular adhesion molecule-1 antisense oligodeoxynucleotides prevents ischemic/reperfusion injury. Transplantation 68(6), 880-887 (1999).
87. Kreis HA, Ponticelli C. Causes of late renal allograft loss: chronic allograft dysfunction, death, and other factors. Transplantation 71(Suppl. 11), SS5-9 (2001).
88. Kahan BD, Rajagopalan PR, Hall M. Reduction of the occurrence of acute cellular rejection among renal allograft recipients treated with basiliximab, a chimeric anti-interleukin-2-receptor monoclonal antibody. United States Simulect Renal Study Group. Transplantation 67(2), 276-284 (1999).
89. Baudouin V, Crusiaux A, Haddad E et al. Anaphylactic shock caused by immunoglobulin E sensitization after retreatment with the chimeric anti-interleukin-2 receptor monoclonal antibody basiliximab. Transplantation 76(3), 459-463 (2003).
90. Barros VR, Rocha V, Garcia VD, Garcia CD. Anaphylactic shock after retreatment with basiliximab. Transplant. Proc. 35(1), 579 (2003).
91. Sollinger H, Kaplan B, Pescovitz MD et al. Basiliximab versus antithymocyte globulin for prevention of acute renal allograft rejection. Transplantation 72(12), 1915-1919 (2001).
92. Bielekova B, Howard T, Packer AN et al. Effect of anti-CD25 antibody daclizumab in the inhibition of inflammation and stabilization of disease progression in multiple sclerosis. Arch. Neurol. 66(4), 483-489 (2009).
93. Oh U, Blevins G, Griffith C et al. Regulatory T cells are reduced during anti-CD25 antibody treatment of multiple sclerosis. Arch. Neurol. 66(4), 471-479 (2009).
94. Rosenberg PB, Vriesendorp AE, Drazner MH et al. Induction therapy with basiliximab allows delayed initiation of cyclosporine and preserves renal function after cardiac transplantation. J. Heart Lung Transplant. 24(9), 1327-1331 (2005).
95. Woodle ES, First MR, Pirsch J, Shihab F, Gaber AO, Van Veldhuisen P. A prospective, randomized, double-blind, placebo-controlled multicenter trial comparing early (7 day) corticosteroid cessation versus long-term, low-dose corticosteroid therapy. Ann. Surg. 248(4), 564-577 (2008).
96. Vincenti F, Grinyo J, Ramos E et al. Can antibody prophylaxis allow sparing of other immunosuppressives? Transplant. Proc. 31(1-2), 1246-1248 (1999).
97. Tran HT, Acharya MK, Mckay DB et al. Avoidance of cyclosporine in renal transplantation: effects of daclizumab, mycophenolate mofetil, and steroids. J. Am. Soc. Nephrol. 11(10), 1903-1909 (2000).
98. Brennan DC, Schnitzler MA. Long-term results of rabbit antithymocyte globulin and basiliximab induction. N. Engl. J. Med. 359(16), 1736-1738 (2008).
99. Pascual M, Theruvath T, Kawai T, Tolkoff-Rubin N, Cosimi AB. Strategies to improve long-term outcomes after renal transplantation. N. Engl. J. Med. 346(8), 580-590 (2002).
100. Magee CC, Pascual M. Update in renal transplantation. Arch. Intern. Med. 164(13), 1373-1388 (2004).
101. Vincenti F, Kirk AD. What's next in the pipeline. Am. J. Transplant. 8(10), 1972-1981 (2008).
102. O'shea JJ, Park H, Pesu M, Borie D, Changelian P. New strategies for immunosuppression: interfering with cytokines by targeting the Jak/Stat pathway. Curr. Opin. Rheumatol. 17(3), 305-311 (2005).
103. Flanagan ME, Blumenkopf TA, Brissette WH et al. Discovery of CP-690,550: a potent and selective Janus kinase (JAK) inhibitor for the treatment of autoimmune diseases and organ transplant rejection. J. Med. Chem. 53(24), 8468-8484 (2010).
104. Lamba M, Tafti B, Melcher M, Chan G, Krishnaswami S, Busque S. Population pharmacokinetic analysis of mycophenolic acid coadministered with either tasocitinib (CP-690,550) or tacrolimus in adult renal allograft recipients. Ther. Drug Monit. 32(6), 778-781 (2010).
105. Van Gurp EA, Schoordijk-Verschoor W, Klepper M et al. The effect of the JAK inhibitor CP-690,550 on peripheral immune parameters in stable kidney allograft patients. Transplantation 87(1), 79-86 (2009).
106. Van Gurp E, Weimar W, Gaston R et al. Phase 1 dose-escalation study of CP-690 550 in stable renal allograft recipients: preliminary findings of safety, tolerability, effects on lymphocyte subsets and pharmacokinetics. Am. J. Transplant. 8(8), 1711-1718 (2008).
107. Borie DC, Larson MJ, Flores MG et al. Combined use of the JAK3 inhibitor CP-690,550 with mycophenolate mofetil to prevent kidney allograft rejection in nonhuman primates. Transplantation 80(12), 1756-1764 (2005).
108. Cohen S, Zwillich SH, Chow V, Labadie RR, Wilkinson B. Co-administration of the JAK inhibitor CP-690,550 and methotrexate is well tolerated in patients with rheumatoid arthritis without need for dose adjustment. Br. J. Clin. Pharmacol. 69(2), 143-151 (2010).
109. Gupta P, Friberg LE, Karlsson MO, Krishnaswami S, French J. A semi-mechanistic model of CP-690,550-induced reduction in neutrophil counts in patients with rheumatoid arthritis. J. Clin. Pharmacol. 50(6), 679-687 (2010).
110. Ghoreschi K, Jesson MI, Li X et al. Modulation of Innate and Adaptive Immune Responses by Tofacitinib (CP-690,550).J. Immunol. 186(7), 4234-4243 (2011).
111. Roffey J, Rosse C, Linch M, Hibbert A, Mcdonald NQ, Parker PJ. Protein kinase C intervention: the state of play. Curr. Opin. Cell Biol. 21(2), 268-279 (2009).
112. Kovarik JM, Steiger JU, Grinyo JM et al. Pharmacokinetics of sotrastaurin combined with tacrolimus or mycophenolic acid in de novo kidney transplant recipients. Transplantation 91(3), 317-322 (2011).
113. Weckbecker G, Pally C, Beerli C et al. Effects of the novel protein kinase C inhibitor AEB071 (Sotrastaurin) on rat cardiac allograft survival using single agent treatment or combination therapy with cyclosporine, everolimus or FTY720. Transpl. Int. 23(5), 543-552 (2010).
114. Skvara H, Dawid M, Kleyn E et al. The PKC inhibitor AEB071 may be a therapeutic option for psoriasis. J. Clin. Invest 118(9), 3151-3159 (2008).
115. Billingham RE, Brent L, Medawar PB. Actively acquired tolerance of foreign cells. Nature 172(4379), 603-606 (1953).
116. Pilat N, Wekerle T. Transplantation tolerance through mixed chimerism. Nat. Rev. Nephrol. 6(10), 594-605 (2010).
117. Fehr T, Sykes M. Clinical experience with mixed chimerism to induce transplantation tolerance. Transpl. Int. 21(12), 1118-1135 (2008).
118. Siemionow M, Nasir S. Chimerism and bone marrow based therapies in transplantation. Microsurgery 27(5), 510-521 (2007).
119. Sayegh MH, Fine NA, Smith JL, Rennke HG, Milford EL, Tilney NL: Immunologic tolerance to renal allografts after bone marrow transplants from the same donors. Ann. Intern. Med. 114(11), 954-955 (1991).
120. Kawai T, Cosimi AB, Spitzer TR et al. HLA-mismatched renal transplantation without maintenance immunosuppression. N. Engl. J. Med. 358(4), 353-361 (2008).
121. Locascio SA, Morokata T, Chittenden M et al. Mixed chimerism, lymphocyte recovery, and evidence for early donor-specific unresponsiveness in patients receiving combined kidney and bone marrow transplantation to induce tolerance. Transplantation 90(12), 1607-1615 (2010).
122. Arslan E, Klimczak A, Siemionow M. Chimerism induction in vascularized bone marrow transplants augmented with bone marrow cells. Microsurgery 27(3), 190-199 (2007).
123. Siemionow M, Zielinski M, Ozmen S, Izycki D. Intraosseus transplantation of donor-derived hematopoietic stem and progenitor cells induces donor-specific chimerism and extends composite tissue allograft survival. Transplantation proceedings 37(5), 2303-2308 (2005).
124. Ozer K, Izycki D, Zielinski M, Siemionow M. Development of donor-specific chimerism and tolerance in composite tissue allografts under αβ-T-cell receptor monoclonal antibody and cyclosporine a treatment protocols. Microsurgery 24(3), 248-254 (2004).
125. Miller SD, Wetzig RP, Claman HN. The induction of cell-mediated immunity and tolerance with protein antigens coupled to syngeneic lymphoid cells. J. Exp. Med. 149, 758-773 (1979).
126. Luo X, Pothoven KL, Mccarthy D et al. ECDI-fixed allogeneic splenocytes induce donor-specific tolerance for long-term survival of islet transplants via two distinct mechanisms. Proc. Natl Acad. Sci. USA 105(38), 14527-14532 (2008).
127. + cytotoxic T cells. J. Virol, 81(12), 6584-6593 (2007).
128. Mcrae BL, Vanderlugt CL, Dal Canto MC, Miller SD. Functional evidence for epitope spreading in the relapsing pathology of experimental autoimmune encephalomyelitis. J. Exp. Med. 182(1), 75-85 (1995).
129. Peterson JD, Karpus WJ, Clatch RJ, Miller SD. Split tolerance of Th1 and Th2 cells in tolerance to Theiler's murine encephalomyelitis virus. Eur. J. Immunol. 23, 46-55 (1993).
130. Fife BT, Guleria I, Gubbels Bupp M et al. Insulin-induced remission in new-onset NOD mice is maintained by the PD-1-PD-L1 pathway. J. Exp. Med. 203(12), 2737-2747 (2006).
131. Brinkmann V, Billich A, Baumruker T et al. Fingolimod (FTY720): discovery and development of an oral drug to treat multiple sclerosis. Nat. Rev. Drug Discov. 9(11), 883-897 (2010).